Chemical Business Newsbase articles from January 2011

Chemical Business Newsbase archives from January 2011

BP spill drove UK dividends to fall by GBP 2 bn last year.
January 31, 2011... The Gulf of Mexico oil spill caused a GBP 2 bn fall in the dividends paid out by British-listed companies in 2010, Capita Registrar's Dividend Monitor will reveal on 31 Jan 2011. BP's decision to suspend payments was almost solely responsible...

Tensions rise as Russian partner threatens block to BP dividend.
January 31, 2011... Tensions are set to increase between BP and its partner in the TNK-BP joint venture, as the Russian billionaires meet today over whether to block around a $1 bn in dividend payments owed to the UK-listed oil giant. The Alfa-Access-Renova (AAR)...

To boost cancer-fighting benefits, eat broccoli with a side of sprouts.
January 31, 2011... A new University of Illinois study provides convincing evidence that the way you prepare and eat your broccoli matters, and also suggests that pairing broccoli with broccoli sprouts may make the vegetable's anti-cancer effect almost twice as...

Ineos and Sinopec sign memorandum for construction of phenol plant.
January 31, 2011... Ineos Phenol and Sinopec Yangzi Petrochemical have signed a memorandum of understanding for a phenol/acetone joint venture in the Nanjing Chemical Industrial Park. The new plant will have capacity of 400,000 tonnes/y phenol and 250,000 tonnes/y...

Questions and answers on the withdrawal of the marketing authorisation application for Ozespa (briakinumab).
January 31, 2011... On 14 Jan 2011, Abbott Laboratories Ltd officially notified the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Ozespa...

Questions and answers: Withdrawal of the marketing authorisation application for Tekinex (omacetaxine mepesuccinate).
January 31, 2011... On 11 Jan 2011, ChemGenex Europe SAS officially notified the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Tekinex...

Pharmacovigilance Working Party (PhVWP), Jan 2011 plenary meeting: Insulin products: Consistent product information regarding the risk of heart failure with concomitant use of pioglitazone.
January 31, 2011... Given recent agreement to implement warnings in the product information for pioglitazone and centrally authorised insulin products with regard to the risk of heart failure in causal association with their combined use, the European Medicines...

Brazil Suzano concludes acquisition of Conpacel stake.
January 31, 2011... Brazil's Suzano Papel e Celulose has got hold of 50% stake in the Conpacel joint venture from its partner Fibria Celulose for R$ 1.45 bn. The acquisition is expected to generate synergies of R$ 300 M by 2012 end.

Brazil Dec oil output at record 2.18 M bbls/day, up 4.4% versus Nov - ANP.
January 31, 2011... In Dec 2010, Brazil's oil output increased 4.4% over Nov 2010 to 2.18 M bbls/day. The figures were released by fuels sector regulator ANP. Of the total oil output in Dec 2010, Petrobras' contribution was 92.9%. The country's natural gas output...

Organizational changes at Bayer HealthCare.
January 31, 2011... Bayer HealthCare has presented a number of measures to implement the initiatives for more innovation and growth announced in Nov 2010. The Bayer subgroup plans to streamline its administration functions in Germany and the US. This measure and...

Celanese announces global price increases for POM, Polyester and LFT.
January 31, 2011... On 31 Jan 2010, Celanese Corp, and its Ticona engineering polymers business, announced it will increase prices worldwide for the following products: Hostaform, Celcon and Amcel acetal copolymer (POM) by up to $0.27/kg or higher on selected...

Clariant OBAs at forefront of REACH registration.
January 31, 2011... As of Jan 2011, Clariant's entire range of Leucophor optical brighteners (OBAs) on general sale in Europe comprises substances which are fully-registered under REACH. The first phase of REACH, the Registration, Evaluation, Authorization and...

85 years of iron oxide color pigments from Uerdingen.
January 31, 2011... For 85 years, Bayferrox iron oxides from Krefeld-Uerdingen have been adding color to building projects around the world. Customers in a wide variety of industries have full confidence in these pigments. Since production started back in 1926,...

Packaged medicines market in Russia was up.
January 31, 2011... Farmexpetr (Russia) reported in 2010 domestic retail trade of pharmaceuticals increased by 8.5% compared to the same of 2009 up to Roubles 404.5 bn. In 2009 the increase was 29% compared to 2008. In 2010 4.4 bn packages of medicines were sold....

New and generic drug approvals: Ondansetron Hydrochloride Oral Solution, Amneal Pharms. [1 table in original article].
January 31, 2011... On 31 Jan 2011, the US Food and Drug Administration announced approval of ANDA 091483 for Ondansetron Hydrochloride Oral Solution. The product contains ondansetron hydrochloride at 4mg/5ml (eq base), is manufactured by Amneal Pharms, and is...

New and generic drug approvals: Phentermine Hydrochloride Oral Tablet, Epic Pharma. [1 table in original article].
January 31, 2011... On 31 Jan 2011, the US Food and Drug Administration announced approval of NDA 200272 for Phentermine Hydrochloride Oral Tablet. The product contains phentermine hydrochloride at 37.5mg, is manufactured by Epic Pharma, and is prescription only....

New and generic drug approvals: Levofloxacin Oral Tablet, Hikma Pharms.
January 31, 2011... On 31 Jan 2011, the US Food and Drug Administration announced the tentative approval of ANDA 078767 for Levofloxacin Oral Tablet. The product contains levofloxacin at 250mg, 500mg, or 750mg and is manufactured by Hikma Pharms. There are no...

New and generic drug approvals: Glipizide and Metformin Hydrochloride Oral Tablet, Zydus Pharms USA. [3 tables in original article].
January 31, 2011... On 31 Jan 2011, the US Food and Drug Administration announced approval of ANDA 078905 for Glipizide and Metformin Hydrochloride Oral Tablet. The product contains glipizide at 2.5mg or 5mg and metformin hydrochloride at 250mg or 500mg (three...

NTPC Vidyut to start getting solar power by Oct 2011.
January 31, 2011... NTPC Vidyut Vyapar Nigam expects to start procuring power generated from solar energy that will be grid connected by Oct 2011 from the existing photovoltaic developers. NTPC expects to procure 54 MW of solar power. The grid connectivity of 36...

Vamshi Rubber: Results for 3Q 2010-2011.
January 31, 2011... Vamshi Rubber Ltd has recorded a net profit-after-tax of Rup 51.90 lakhs on net sales/income from operations of Rup 1,900.09 lakhs for 3Q ended Dec 2010 (net profit-after-tax of Rup 80.39 lakhs on net sales/income from operations of Rup 1,199.53...

High Energy Batteries: Results for 3Q 2010-2011.
January 31, 2011... Lead acid storage batteries manufacturer High Energy Batteries (India) Ltd has reported a net profit of Rup 18.05 lakhs on net sales of Rup 1,118.34 lakhs for 3Q ended Dec 2010 (net loss of Rup 28.13 lakhs on net sales of Rup 783.34 lakhs in 3Q...

Suven Life Sciences Ltd spends 24% of revenue on R&D PAT up by 55% for the 3Q ending Dec 2010.
January 31, 2011... Suven Life Sciences Ltd (Suven) announced its unaudited financial results for 3Q ended Dec 2010. Financial Highlights for nine months ending Dec 2010: Growth in revenue 12.65% at Rup 1052 M (Rup 934 M in nine months ended Dec 2009) Growth in...

Array BioPharma reports financial results for 2Q 2010-2011.(Financial report)
January 31, 2011... Array BioPharma Inc reported financial results for 2Q and 1H ended Dec 2010. Array BioPharma reported revenue of $16.5 M for 2Q 2010-2011, ($9.6 M in 2Q 2009-2010). The company spent $14.5 M in proprietary research and development for 2Q...

Parexel reports 2Q 2010-2011 financial results.(Financial report)
January 31, 2011... Parexel International Corp (Parexel) announced its financial results for 2Q and 1H ended Dec 2010. For 2Q 2010-2011, Parexel's consolidated service revenue increased by 6.9% to $304.4 M, ($284.7 M in 2Q 2009-2010). GAAP net income for 2Q...

Hologic announces 1Q 2010-2011 operating results.(Financial report)
January 31, 2011... Hologic Inc announced its results for 1Q ended 25 Dec 2010. Revenues totalled $432.6 M, for 1Q 2010-2011 (+4.9% over $412.4 M in 1Q 2009-2010). The increase was primarily attributable to: Growth in Breast Health revenues of $16.3 M, or 9.1%,...

Olin announces 4Q 2010 earnings.(Financial report)
January 31, 2011... Olin Corp announced results for 4Q and year ended Dec 2010. Net income was $2 M, or $0.02/diluted share for 4Q 2010, (net income of $21.8 M, or $0.28/diluted share in 4Q 2009). Sales in 4Q 2010 were $385.4 M, ($350.9 M in 4Q 2009). The results...

Hoya announces 3Q 2010-2011 financial results.(Financial report)
January 31, 2011... Hoya Corp announced financial results for 3Q ended Dec 2010. Net sales were up 1.5% to Yen 108,449 M, and operating income rose 4.7% to Yen 19,897 M during 3Q 2010-2011. Net income was up 12% to Yen 13,210 M, and earnings/share were Yen 30.62...

Eastman Chemical announces 4Q and FY 2010 results:.(Financial report)
January 31, 2011... For its 4Q 2010, Eastman Chemical Co has announced sales of $1463 M ($1186 M for its 4Q 2009), of which: the US and Canada accounted for $704 M ($597 M), Asia Pacific $388 M ($293 M), Europe, the Middle East & Africa $299 M ($230 M), and...

Eastman Chemical announces 4Q and FY 2010 results: Coatings, Adhesives, Speciality Polymers, and Inks.(Financial report)
January 31, 2011... For its 4Q 2010, the Coatings, Adhesives, Speciality Polymers, and Inks segment of Eastman Chemical Co has announced sales of $379 M ($327 M for its 4Q 2009) and operating income of $53 M ($76 M). For its fiscal 2010, this segment has announced...

Eastman Chemical announces 4Q and FY 2010 results: Fibres.(Financial report)
January 31, 2011... For its 4Q 2010, the Fibres segment of Eastman Chemical Co has announced sales of $300 M ($253 M for its 4Q 2009) and operating income of $78 M ($73 M). For its fiscal 2010, this segment has announced sales of $1142 M ($1032 M for its fiscal...

Eastman Chemical announces 4Q and FY 2010 results: Performance Chemicals and Intermediates.(Financial report)
January 31, 2011... For its 4Q 2010, the Performance Chemicals and Intermediates segment of Eastman Chemical Co has announced sales of $526 M ($401 M for its 4Q 2009) and operating income of $51 M ($25 M). For its fiscal 2010, this segment has announced sales of...

Eastman Chemical announces 4Q and FY 2010 results: Speciality Plastics.(Financial report)
January 31, 2011... For its 4Q 2010, the Speciality Plastics and Intermediates segment of Eastman Chemical Co has announced sales of $258 M ($205 M for its 4Q 2009) and operating income of $24 M ($9 M). For its fiscal 2010, this segment has announced sales of $1043...

Eastman Chemical announces 4Q and FY 2010 results: Discontinued operations.(Financial report)
January 31, 2011... On 31 Jan 2011, Eastman Chemical Co completed the sale of the polyethylene terephthalate (PET) business, related assets at the Columbia, SC, site and technology of its Performance Polymers segment. The PET business, assets, and technology were...

Pacific Biosciences announces favourable ruling in patent interference case with Life Technologies.
January 31, 2011... Pacific Biosciences of California Inc (Pacific Biosciences) announced that the Board of Patent Appeals and Interferences of the US Patent and Trademark Office (USPTO) has rendered a decision in a previously announced patent interference provoked...

Research and Markets: South Africa Pharmaceuticals and Healthcare Report 1Q 2011.(Report)
January 31, 2011... Research and Markets has announced the addition of the South Africa Pharmaceuticals and Healthcare Report 1Q 2011 report to their offering. The South Africa Pharmaceuticals and Healthcare Report provides industry professionals and strategists,...

Oragenics Inc announces a second Phase I clinical trial of Smart replacement therapy.
January 31, 2011... Florida based biopharmaceutical company Oragenics Inc announced its intention to commence a second Phase I clinical trial of Smart replacement therapy. The company has retained PRA International (PRA) as the Clinical Research Organization for...

Maxygen announces initiation of Phase I clinical trial under Perseid's collaboration with Astellas for Ctla4-Ig programme.
January 31, 2011... Maxygen Inc a biotechnology company focused on the development of improved protein drugs announced the initiation of a Phase I clinical study to evaluate a next generation Ctla4-Ig therapeutic that is being developed by Perseid Therapeutics Llc...

Pfizer completes tender offer for shares of King Pharmaceuticals Inc.
January 31, 2011... Pfizer Inc announced that its wholly-owned subsidiary, Parker Tennessee Corp, has accepted for purchase all of the shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of King...

Allergan and MAP Pharmaceuticals announce collaboration on LEVADEX investigational therapy for acute migraine.
January 31, 2011... Allergan Inc and MAP Pharmaceuticals Inc announced collaboration within the US for LEVADEX, a self-administered, orally inhaled therapy that has completed Phase III clinical development for the treatment of acute migraine in adults. MAP...

VBL announces initiation of two clinical trials for VB-111, targeted, dual-action, anti-angiogenic, vascular disruptive agent for cancer.
January 31, 2011... VBL Therapeutics (VBL) announced the initiation of two studies to further evaluate the efficacy and safety of VB-111 in advanced cancers. The first, a Phase IIa study, will evaluate the efficacy and safety of VB-111 among patients with advanced...

GATTEX (teduglutide) meets primary efficacy endpoint in Phase III pivotal study in patients with adult short bowel syndrome.(Clinical report)
January 31, 2011... NPS Pharmaceuticals Inc (NPS) announced that its Phase III pivotal study of GATTEX (teduglutide) met the primary efficacy endpoint of reducing parenteral nutrition dependence in patients with adult short bowel syndrome. The 24-week randomised,...

Alexion acquires Taligen Therapeutics and Creates Translational Medicine Group to accelerate development of expanded portfolio.
January 31, 2011... Alexion Pharmaceuticals Inc (Alexion) has acquired Taligen Therapeutics Inc (Taligen), a privately held development-stage biotechnology company based in Cambridge, MA. The acquisition broadens Alexion's portfolio of product candidates and...

Phenomenex Inc and Vista Analytical announce new method for dioxin analysis in animal feed.
January 31, 2011... Phenomenex Inc has announced the publication of a new method for the analysis of dioxins in animal feed and tissue using high-resolution gas chromatography with mass spec detection. Demand for these analyses has grown significantly in recent...

Antisoma plc's leukaemia drug fails at Phase III.
January 31, 2011... Antisoma plc has announced that the ACCEDE Phase III trial of AS1413 (amonafide) in secondary acute myeloid leukaemia (secondary AML) did not meet its primary endpoint. Development of AS1413 will be discontinued. Antisoma has not seen a benefit...

Depomed Inc's shingles drug gets OK from FDA.
January 31, 2011... Depomed Inc has announced that US FDA has approved Gralise (gabapentin) tablets for once-daily treatment of post-herpetic neuralgia, which is pain following healing of the rash associated with shingles. Gralise was developed by Depomed and is...

Pharming Group discontinues funding of DNage.
January 31, 2011... Pharming Group NV (Pharming) has announced that it has discontinued the funding of DNage. In Jul 2010, Pharming announced the completion of the spin-off of its subsidiary DNage. As part of the spin-off agreement, Pharming agreed to provide DNage...

The 20 Jan 2011 Safety Monitoring Committee Meeting for Nymox Pharmaceutical pivotal Phase III NX-1207 trials indicates favourable safety profile.
January 31, 2011... Nymox Pharmaceutical Corp (Nymox) has provided an update on the company's Phase III pivotal trials for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The Safety Monitoring Committee meeting of 28 Jan 2011 was...

Molecular Insight Pharmaceuticals Inc faces uncertain future in Chapter 11.
January 31, 2011... Molecular Insight Pharmaceuticals Inc (Molecular Insight) has announced that it has received approval from the US Bankruptcy Court for the District of Massachusetts of its motion to assume the previously announced investment agreement entered...

MorphoSys AG reaches clinical milestone with OncoMed Pharmaceuticals Inc.
January 31, 2011... MorphoSys AG has received a milestone payment from OncoMed Pharmaceuticals (OncoMed) in connection with the initiation of a Phase I clinical trial with a HuCAL-derived, fully human antibody. The antibody OMP-59R5, which is part of OncoMed's...

Manhattan Pharmaceuticals achieves Ariston merger milestone.
January 31, 2011... Manhattan Pharmaceuticals Inc announced that the company's Board of Directors has decided to continue development of AST-915, an orally delivered treatment for essential tremor. This decision was made following the announcement of favourable...

Peregrine Pharmaceuticals Inc completes patient enrolment in Phase Ib HCV/HIV coinfection trial.
January 31, 2011... Peregrine Pharmaceuticals Inc (Peregrine) announced the completion of enrolment in the company's Phase Ib dose escalation safety study of bavituximab in patients coinfected with chronic hepatitis C virus (HCV) and HIV. Previously in Jan 2011,...

MorphoSys AG reaches clinical milestone with Pfizer Inc.
January 31, 2011... MorphoSys AG has received a milestone payment from Pfizer in connection with the IND filing in Dec 2010 and subsequent initiation of a Phase I clinical trial of a HuCAL-derived, fully human antibody in the therapeutic area of oncology. MorphoSys...

Johnson & Johnson receives approval from European Commission.
January 31, 2011... Johnson & Johnson and Crucell have announced that the European Commission has granted approval for Johnson & Johnson's proposed acquisition of Crucell. Reference is made to the joint press release of Johnson & Johnson and Crucell NV...

Oxford BioMedica plc acquires GMP manufacturing facility.
January 31, 2011... Oxford BioMedica plc has announced that it has agreed to acquire a manufacturing facility based in Oxford, UK, from RecipharmCobra Biologics, the specialist biologics division of Recipharm AB, for a purchase price of GBP 1.9 M. The acquisition...

ProMetic Life Sciences Inc announces positive change to terms of secured debt.
January 31, 2011... ProMetic Life Sciences Inc (ProMetic) has announced the restructuring of secured loans provided to the company by a select group of stakeholders. The restructuring arrangements will postpone repayment of C$4 M of ProMetic's secured debt...

Japan's Eisai establishes new US R&D subsidiary to focus on oncology.
January 31, 2011... Japanese drug major Eisai has established a new R&D subsidiary, called H3 Biomedicine (H3B), in Cambridge, MA, USA, to strengthen its research in oncology, and the company's research activities are underway. H3B aims to discover breakthrough...

US FDA clears use of Novartis' Menveo for over two-year-olds; Depomed leaps on approval of shingles drug Gralise.
January 31, 2011... The US Food and Drug Administration (FDA) has approved Swiss drug major Novartis' Menveo [meningococcal (Groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine] for active immunisation to prevent invasive meningococcal...

Eli Lilly and Company files patent suit against Hospira Inc and Jiangsu Hansoh Pharma.
January 31, 2011... Eli Lilly & Co (Lilly) has filed suit against Hospira Inc, seeking to block the company from selling a generic version of its cancer drug Gemzar. The generic Gemzar is made in China by Jiangsu Hansoh Pharmaceutical Co Ltd. According to...

Aosaikang Pharma signs deal with New Zealand diabetes company.
January 31, 2011... Jiangsu Aosaikang Pharmaceutical (Aosaikang Pharma) of Nanjing purchased a 5% stake in a New Zealand pharma, Living Cell Technologies (LCT), for $1.7 M. LCT's major product, Diabecell, is a technology that implants encapsulated islet cells from...

Verona Pharma applies for approval to test RPL554 in UK clinical trials.
January 31, 2011... Verona Pharma plc has applied to the Medicines and Healthcare Products Regulatory Agency (MHRA), the Governmental agency in the UK with responsibility for standards of safety, quality and performance of new drug treatments, to conduct clinical...

Alphalyse Inc receives GLP accreditation to determine serum concentration of protein biologics.
January 31, 2011... Alphalyse has received Good Laboratory Practice (GLP) accreditation by the Danish Medicines Agency, and now performs protein analysis in compliance with the OECD principles of GLP. Alphalyse provides development of protein specific...

Ascenion GmbH release: non-hallucinogenic LSD derivative for treating cluster headache; has acquired an equity stake in Entheogen Corp.
January 31, 2011... Ascenion GmbH has announced that it has acquired an equity stake in Entheogen Corp. The US-based start-up was jointly established in order to develop a non-hallucinogenic LSD derivative for the treatment of cluster headache. The neurological...

Neumedicines Inc receives notice of allowance for patent covering use of HemaMax (rIL-12) to treat chemotherapy-induced thrombocytopenia.
January 31, 2011... Neumedicines Inc has announced that it has received a notice of allowance from the US Patent and Trademark Office (USPTO) for its US patent application number 10/886,267 entitled 'Uses of IL-12 in Haematopoiesis.' The notice of allowance is the...

Plasticell completes GBP 3.5 M financing round.
January 31, 2011... Plasticell has announced it has completed a two-part equity financing, raising a total of GBP 3.5 M from new and existing investors. The first tranche of the financing, in which GBP 1.5 M was drawn down in Apr 2009, was used to develop...

Onyx Pharmaceuticals receives fast track designation for carfilzomib; company initiates rolling NDA submission for accelerated approval.
January 31, 2011... Onyx Pharmaceuticals Inc (Onyx) announced that the US Food and Drug Administration (FDA) has granted fast track designation for carfilzomib, a next generation proteasome inhibitor for the potential treatment of patients with relapsed and...

ImaginAb Inc and Eurogentec SA collaborate to produce antibody fragments in Pichia.
January 31, 2011... ImaginAb Inc and Eurogentec SA announced a development collaboration to establish a novel system for producing engineered antibody fragments. The two companies will produce ImaginAb's optimized antibody fragments with Eurogentec's...

Avanir Pharmaceuticals announces US launch and availability of Nuedexta for pseudobulbar affect.
January 31, 2011... Avanir Pharmaceuticals Inc (Avanir) announced that Nuedexta (dextromethorphan hydrobromide and quinidine sulfate) is now available by prescription in the US. Nuedexta is the first and only treatment approved by the US Food and Drug...

Laureate Pharma changes name to Laureate Biopharmaceutical Services Inc.
January 31, 2011... Laureate Pharma Inc has changed its name to Laureate Biopharmaceutical Services Inc (Laureate Biopharma) to better describe the company's positioning in the biopharmaceutical industry. The company's logo has been updated to emphasize 'Laureate'...

Endologix announces favourable clinical results for Nellix technology.(Financial report)(Clinical report)
January 31, 2011... Endologix Inc announced the publication of favourable clinical results for the Nellix technology for the endovascular repair of abdominal aortic aneurysm (EVAR). The peer-reviewed article reported initial results from the international...

Bayer Animal Health announces the launch of Advantage II and K9 Advantix II.
January 31, 2011... Bayer Animal Health announced in Feb 2011 at the North American Veterinary Conference, the availability of its new products: Advantage II for cats and dogs, and K9 Advantix II for dogs. These products combine the adulticidal properties of the...

Final results from Ergoflex study show statistically significant reduction in joint pain in as little as one week.(Clinical report)
January 31, 2011... Oxis International Inc (Oxis) announced highly favourable final results from an initial clinical study to assess the beneficial effects of its patent-pending Ergoflex joint health formula, launched commercially in Dec 2010. Specifically, the...

Interleukin (IL)-12 secretion can predict potency of Argos Therapeutics' Arcelis dendritic cell (DC) immunotherapy and can be used as potency marker in Phase III clinical trial.
January 31, 2011... Argos Therapeutics (Argos) announced that interleukin (IL)-12 secretion can predict the potency of the company's Arcelis dendritic cell (DC) immunotherapy and can be used as a potency marker in a Phase III clinical trial testing the company's...

Sinovac Biotech files clinical trial applications with SFDA for its proprietary pneumococcal polysaccharides vaccines (PPV)..
January 31, 2011... Sinovac Biotech Ltd (Sinovac) announced the submission of the applications to commence human clinical trials for its 23-valent and 24-valent pneumococcal polysaccharides vaccines to the Chinese State Food Drug Administration (SFDA) on 31 Jan...

Caliper Life Sciences launches microfluidic LabChip DS platform for UV/VIS spectral analysis of nucleic acid and protein samples.
January 31, 2011... Caliper Life Sciences Inc (Caliper) announced that Caliper and Trinean NV have agreed to a long-term, exclusive arrangement under which Caliper will distribute Trinean's DropSense platform under the name LabChip DS in North America. With the...

Kensey Nash acquires medical adhesives and coatings technology.
January 31, 2011... Kensey Nash Corp has acquired the assets of privately held Nerites Corp, a developer of medical adhesives and anti-fouling coatings based in Madison, WI for $20 M in cash. Nerites is developing a technology platform of adhesive-based...

Bohai Pharmaceuticals receives two-year research grant from the Chinese Government to fund development of a TCM product.
January 31, 2011... Bohai Pharmaceuticals Group Inc (Bohai) has received a two-year government research grant totalling $144,000 to fund the research and development of Menstrual Relief Tablet, a traditional Chinese medicine (TCM) for dysmenorrhoea, or menstrual...

Masimo and Covidien announce extension of royalty agreement.
January 31, 2011... Masimo and Covidien have amended the existing settlement agreement initially reached in Jan 2006. Under the terms of the amendment, Covidien will pay Masimo a royalty of 7.75% for its current pulse oximetry products sold in the US for three...

University of Southampton and Inovio Pharmaceuticals initiate Phase II clinical study to evaluate leukaemia DNA vaccine using electroporation delivery technology.
January 31, 2011... Inovio Pharmaceuticals Inc (Inovio) announced the regulatory approval of a Phase II clinical trial (WIN Trial) to treat leukaemia utilizing Inovio's new ELGEN 1000 automated vaccine delivery device. This open-label, multi-centre clinical trial...

Endo Pharmaceuticals announces receipt of Paragraph IV Certification.
January 31, 2011... Endo Pharmaceuticals announced that its partners, Teikoku Seiyaku Co Ltd and Teikoku Pharma USA Inc, have received a Paragraph IV Certification Notice from Mylan Technologies Inc (Mylan) advising of the filing of an Abbreviated New Drug...

AMT receives EUR 1.1 M funding for Acute Intermittent Porphyria gene therapy as part of EU consortium grant.
January 31, 2011... Amsterdam Molecular Therapeutics (AMT) announced that the European Union (EU) has finalised a EUR 3.3 M grant to the AIPGENE consortium, of which AMT is a member, for the development of a gene therapy product for Acute Intermittent Porphyria...

Sigma-Aldrich continues to expand analytical suite with Resource Technology Corp acquisition.
January 31, 2011... Sigma-Aldrich Corp has acquired the assets of Resource Technology Corp (RTC) of Laramie, WY, an industry leader in analytical standards and certified reference materials. The acquisition of RTC's business complements the recently completed...

Shell initiates market tests of Shell Nitrogen Enriched Diesel.
January 31, 2011... Shell Oil Products US (Shell) announced a test of Shell Nitrogen Enriched Diesel, extending the company's exclusive Nitrogen Enriched advanced cleaning system to diesel. The fuel has been proven to reduce fuel consumption in an extensive test of...

The Valence Group announces successfully advising Cytec Industries Inc on the sale of its Building Block Chemicals Business.
January 31, 2011... The Valence Group has successfully advised Cytec Industries Inc on the sale of its Building Block Chemicals Business, with 2010 sales of $600 M, to an affiliate of HIG Capital LLC. Total consideration to be received of $180 M includes cash...

Holly Corp reports on power failure at its Navajo refinery.
January 31, 2011... Holly Corp's Navajo Refinery in Artesia, NM experienced a plant-wide power failure late in the day on 26 Jan 2011 due to an interruption in power supply from its local utility. Navajo's crude rate has been reduced to approximately 40,000...